| Properties of FDA-approved small molecule protein kinase inhibitors |
104 |
| Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers |
54 |
| Hypertension and cardiovascular risk: General aspects |
52 |
| Astaxanthin: A mechanistic review on its biological activities and health benefits |
49 |
| Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs |
49 |
| Canonical and non-canonical mechanisms of Nrf2 activation |
38 |
| Gut microbiota, a new frontier to understand traditional Chinese medicines |
34 |
| A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy |
33 |
| Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy |
33 |
| Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy |
31 |
| Phytochemicals as inhibitors of NF-kappa B for treatment of Alzheimer's disease |
31 |
| Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway |
30 |
| Pharmacological targeting of RAS: Recent success with direct inhibitors |
28 |
| Targeting ERK1/2 protein-serine/threonine kinases in human cancers |
27 |
| Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms |
27 |
| Regulation of ER-mitochondria contacts by Parkin via Mfn2 |
26 |
| Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: A focus on human studies |
26 |
| Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review |
26 |
| Neurobiological links between depression and AD: The role of TGF-beta 1 signaling as a new pharmacological target |
26 |
| Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors |
25 |
| Therapeutic potential of curcumin in diabetic complications |
25 |
| Dioscin: A diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections |
25 |
| Alzheimer's disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence |
25 |
| Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer's disease: A neuropharmacological review of their bioactive constituents |
24 |
| Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper |
24 |
| Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment |
24 |
| Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents |
23 |
| Possible use of Punica granatum (Pomegranate) in cancer therapy |
23 |
| Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets |
22 |
| Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism |
22 |
| Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade |
22 |
| Relevance of gutmicrobiota in cognition, behaviour and Alzheimer's disease |
22 |
| Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota |
21 |
| Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway |
21 |
| Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases |
21 |
| A new dawn for managing dyslipidemias: The era of ma-based therapies |
21 |
| Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention |
21 |
| The clinical efficacy of curcumin-containing nutraceuticals: An overview of systematic reviews |
20 |
| Natural products targeting ER stress pathway for the treatment of cardiovascular diseases |
20 |
| Long noncoding RNAs act as regulators of autophagy in cancer |
20 |
| A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review |
20 |
| Potential role of genipin in cancer therapy |
20 |
| Targeting oncogenic Raf protein-serine/threonine kinases in human cancers |
20 |
| Tocotrienols: The promising analogues of vitamin E for cancer therapeutics |
20 |
| Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases |
20 |
| NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia |
19 |
| Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy |
19 |
| Beyond a neurotransmitter: The role of serotonin in inflammation and immunity |
19 |
| Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) |
19 |
| The beneficial roles of metformin on the brain with cerebral ischaemia/reperfusion injury |
19 |
